CA-VERIMATRIX
3.9.2024 17:46:29 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX, FR0010291245), a global leader in powering the modern connected world with people-centered security, today announced its exciting plans for IBC 2024 taking place from September 13-17 in Amsterdam. Verimatrix’s IBC booth 1.C65 is set to become "Broadcast Beach," a vibrant, surf and sand-themed experience designed to transport attendees to the sunny shores of San Diego (home of Verimatrix’s U.S. office), while showcasing the company’s robust suite of security solutions, including its latest anti-piracy solution, Counterspy.
Counterspy, a new product in the Verimatrix Streamkeeper family, is a groundbreaking solution designed to tackle the escalating threat of digital video piracy in bold new ways. It offers unparalleled protection with a focus on tangible revenue-saving benefits for customers. IBC attendees will be able to experience a live demonstation that showcases how Counterspy customers can:
- Reduce Video Piracy: Counterspy provides a formidable defense against unauthorized access, significantly cutting down on piracy incidents and securing content across platforms.
- Protect Media Apps: With its advanced app protection and telemetry features, Counterspy shields media apps from reverse engineering, man-in-the-middle attacks, and other malicious activities, ensuring that only legitimate users can access content – and providing customers with a way to monitor and respond to piracy threats in real-time.
- Unlock Access to More Premium Content: By safeguarding content with Counterspy, operators can confidently expand their premium content offerings, meeting studio security requirements.
- Reduce CDN Costs: Counterspy directly addresses the issue of CDN leeching, enabling operators to cut CDN costs dramatically (one Verimatrix customer saw their CDN expenses drop by 50% after implementing Counterspy)
- Boost Paid Subscribers: By enhancing content security and reducing piracy, Counterspy helps customers maintain a trustworthy service vs. pirate services, which in turn helps drive subscriber growth and revenue.
The Verimatrix Broadcast Beach-themed booth at IBC 2024 will feature:
- Surfside Check-In: The first stop in the serene beachfront oasis where attendees can check in with a host and grab some wave-breaking Verimatrix swag.
- Counterspy Cove: Grab a seat at one of the high-back deck tables and interact with a live demo for Verimatrix Counterspy, the ultimate in video security defense, seamlessly shielding media apps from piracy, preventing CDN leeching, reducing credential theft, and ensuring substantial revenue protection.
- Revenue Protection Cabanas: Reserve a cabana equipped with hammocks and interactive displays to comfortably engage with and learn about award-winning Verimatrix Streamkeeper solutions.
- Cyber Surf Shack: Dive into a surf-themed espresso bar adorned with surfboards and beach cruisers, symbolizing Verimatrix’s agility and adaptability.
Attendees are invited to kick off their shoes and soak up some fun in the sun while staff from Verimatrix highlight the latest in secure streaming, bulletproof cybersecurity, and layered anti-piracy measures. To book at meeting with a Verimatrix security specialist during IBC 2024, email dvanmeter@verimatrix.com or alternatively, book a meeting online.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit https://www.verimatrix.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903597006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom